Clinical Trial Update: Xarelto Regulatory Post-Marketing Surveillance

View source ↗

Summary

This update reports results from Bayer’s post-marketing surveillance study of rivaroxaban (Xarelto) in patients with venous thromboembolism, evaluating real-wor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• Xarelto (rivaroxaban)

Snippet

Sponsor: Bayer | Conditions: Venous Thromboembolism | Status: COMPLETED